MLC Medical LLC has entered into an agreement with SK Plasma Co., Ltd., a specialized South Korean manufacturer of plasma-derived therapeutics, to supply critical biological agents to Georgian medical facilities.

The agreement covers the registration and distribution of essential plasma-derived therapies, notably SK Albumin 20% (Human Serum Albumin) and LIV-GAMMA SN (Human Normal Immunoglobulin G). These preparations are indispensable across hospital emergency units, surgical wards, and intensive care protocols for plasma volume maintenance and primary or secondary immune support.

Adding SK Plasma’s product line directly supports MLC Medical’s strategy to alleviate shortages of critical hospital blood derivatives and guarantee consistent product availability for high-acuity clinical cases.

We look forward to working closely with SK Plasma to supply healthcare practitioners across Georgia with reliable plasma products produced to rigorous international safety benchmarks.